Business
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025
LYON, France, May 13, 2025--MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025
About this update from Maat Pharma
LYON, France, May 13, 2025 --( BUSINESS WIRE )--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today provided a business update and reported its cash position as of March 31, 2025. "The first months of 2025 have marked a pivotal moment for MaaT Pharma with the positive results from our Phase 3 trial of MaaT013, our lead asset. This milestone enables us to advance toward a Market Authorization submission in Europe and reflects over a decade of dedication and close collaboration with physicians. We are deeply grateful for the trust and participation of patients, whose support has been essential in achieving this progress," said Hervé Affagard, CEO and co-founder of MaaT Pharma . "We are also making strong progress across our pipeline, with encouraging outcomes for MaaT033 and MaaT034. Additionally, by extending our cash runway to October 2025, we are well-positioned to deliver on our upcoming value-creating milestones." Pipeline highlights In Hemato-Oncology Acute Graft-versus-Host Disease (aGvHD) – MaaT013 Allogenic Hematopoietic Stem Cell Transplant (allo-HSCT) - MaaT033 In Immuno-Oncology MaaT034 - Next-generation drug candidates with co-cultured technology (MET-C platform) MaaT013– Proof-of-Concept trials with donor derived drugs (MET-N platform) In Neurodegenerative Diseases Amyotrophic Lateral Sclerosis (ALS) - MaaT033 Corporate update Cash position 1 Revenues in Q1 2025 1 Upcoming financial communications* *Indicative calendar that may be subject to change. Upcoming investor and business conferences participation --- About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim", "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. 1 unaudited financial results View source version on businesswire.com: https://www.businesswire.com/news/home/20250513051655/en/ Contacts MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected] Rx Communications Group – U.S. Investor Relations Michael Miller Managing Director +1-917-633-6086 [email protected] MaaT Pharma – Media Relations Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 [email protected] Catalytic Agency – U.S. Media Relations Heather Shea Media relations for MaaT Pharma +1 617-286-2013 [email protected]